Veracyte Inc (VCYT) Stock Price, Quote & News

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 243 6300

Fax: 650 243 6388

Website: www.veracyte.com

Address:

6000 Shoreline Court, Suite 300, South San Francisco, United States

Following_the_trend Oct. 22 at 6:43 PM

$VCYT small add today

0 · Reply

PhishTourFunds Oct. 21 at 3:12 AM

$VCYT

1 · Reply

JarvisFlow Oct. 20 at 10:46 AM

Canaccord Genuity has adjusted their stance on Veracyte ( $VCYT ), setting the rating to Hold with a target price of 40.

0 · Reply

JarvisFlow Oct. 17 at 12:23 PM

Freedom Capital Markets updates rating for Veracyte ( $VCYT ) to Buy, target set at 45.

0 · Reply

PhishTourFunds Oct. 17 at 1:34 AM

$VCYT Dead board, original play from late July 50% gainer and holding steady

0 · Reply

RunnerSignals Oct. 16 at 5:22 PM

Fresh highs for $MS $TJX $HCI while $VCYT crosses key MA and $NOMD oversold https://stocksrunner.com/news/2025-10-16-intraday-technical-patterns-show-mixed-signals

0 · Reply

PhishTourFunds Oct. 6 at 7:06 AM

$VCYT $35 target acquired from $23

0 · Reply

SilverEagle Oct. 3 at 5:37 PM

$VCYT ride that ema into year end.

0 · Reply

PhishTourFunds Oct. 1 at 3:51 AM

$VCYT Exclusive play and $35 almost touched twice now

0 · Reply

G101SPM Sep. 29 at 9:47 AM

$VCYT $33.44 HOLDING LONG POSITON. BRIEF: Company announced new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The prostate PAM50 biomarker is currently available for Research Use Only on the Decipher GRID (Genomic Resource for Intelligent Discovery) research tool.

0 · Reply

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Sep 28, 2025, 4:00 PM EDT - 26 days ago

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Sep 24, 2025, 9:00 AM EDT - 4 weeks ago

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Sep 9, 2025, 10:31 PM EDT - 6 weeks ago

Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 9:00 AM EDT - 6 weeks ago

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Aug 29, 2025, 8:30 AM EDT - 2 months ago

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 11:25 AM EDT - 2 months ago

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Aug 26, 2025, 10:18 AM EDT - 2 months ago

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Aug 26, 2025, 8:30 AM EDT - 2 months ago

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Aug 7, 2025, 2:20 AM EDT - 2 months ago

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Veracyte Announces Second Quarter 2025 Financial Results

Jul 17, 2025, 5:30 PM EDT - 3 months ago

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:05 PM EDT - 3 months ago

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

May 28, 2025, 4:05 PM EDT - 5 months ago

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 20, 2025, 5:00 PM EDT - 5 months ago

Veracyte to Participate in Upcoming Investor Conferences

May 8, 2025, 12:49 AM EDT - 6 months ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 6 months ago

Veracyte Announces First Quarter 2025 Financial Results

Apr 25, 2025, 7:00 AM EDT - 6 months ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 22, 2025, 9:00 AM EDT - 6 months ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 21, 2025, 4:05 PM EDT - 6 months ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Mar 25, 2025, 4:05 PM EDT - 7 months ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 19, 2025, 5:00 PM EDT - 7 months ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Feb 25, 2025, 10:32 AM EST - 8 months ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:16 AM EST - 8 months ago

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Feb 24, 2025, 10:53 PM EST - 8 months ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 8 months ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 14, 2025, 8:30 AM EST - 9 months ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 11, 2025, 8:30 AM EST - 9 months ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 5, 2025, 8:30 AM EST - 9 months ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 4, 2025, 4:30 PM EST - 9 months ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Dec 5, 2024, 4:05 PM EST - 11 months ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Nov 6, 2024, 10:49 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 6:43 PM EDT - 1 year ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Sep 15, 2024, 8:45 AM EDT - 1 year ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Aug 26, 2024, 5:30 PM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 9:00 AM EDT - 1 year ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 7, 2024, 2:08 PM EDT - 1 year ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 6, 2024, 10:17 PM EDT - 1 year ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results

Jul 17, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

May 22, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 7, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Apr 22, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 22, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Apr 16, 2024, 8:30 AM EDT - 1 year ago

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Feb 27, 2024, 5:55 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Following_the_trend Oct. 22 at 6:43 PM

$VCYT small add today

0 · Reply

PhishTourFunds Oct. 21 at 3:12 AM

$VCYT

1 · Reply

JarvisFlow Oct. 20 at 10:46 AM

Canaccord Genuity has adjusted their stance on Veracyte ( $VCYT ), setting the rating to Hold with a target price of 40.

0 · Reply

JarvisFlow Oct. 17 at 12:23 PM

Freedom Capital Markets updates rating for Veracyte ( $VCYT ) to Buy, target set at 45.

0 · Reply

PhishTourFunds Oct. 17 at 1:34 AM

$VCYT Dead board, original play from late July 50% gainer and holding steady

0 · Reply

RunnerSignals Oct. 16 at 5:22 PM

Fresh highs for $MS $TJX $HCI while $VCYT crosses key MA and $NOMD oversold https://stocksrunner.com/news/2025-10-16-intraday-technical-patterns-show-mixed-signals

0 · Reply

PhishTourFunds Oct. 6 at 7:06 AM

$VCYT $35 target acquired from $23

0 · Reply

SilverEagle Oct. 3 at 5:37 PM

$VCYT ride that ema into year end.

0 · Reply

PhishTourFunds Oct. 1 at 3:51 AM

$VCYT Exclusive play and $35 almost touched twice now

0 · Reply

G101SPM Sep. 29 at 9:47 AM

0 · Reply

AlertsAndNews Sep. 28 at 10:15 PM

$VCYT Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer New data from the randomized BALANCE trial (NCT03371719) demonstrated that the PAM50 molecular signature can identify which recurrent prostate cancer patients benefit from adding apalutamide to salvage radiation therapy.

0 · Reply

AttractDontChase Sep. 27 at 3:39 AM

IVDA the next life changing small cap run, is on the horizon. IVDA might be the only true AI + drone stock trading this low. Real defense tech. Real installations. Smart surveillance + threat detection is a trillion-dollar theme and this is how you get in early.! $TALK $LVLU $MLGO $CRVS $VCYT

0 · Reply

thecontracap Sep. 22 at 3:25 PM

$MDXH 3.5x rev is $8. $4X rev is $9.50. $VCYT grows half as fast and trades 4.5x.

1 · Reply

PhishTourFunds Sep. 20 at 11:33 PM

$VCYT $35 almost reached 🎯

0 · Reply

SilverEagle Sep. 19 at 1:20 PM

$VCYT busting through. Let’s get weekly closes > 35

1 · Reply

PhishTourFunds Sep. 5 at 3:13 PM

$VCYT

0 · Reply

NVDAMillionaire Sep. 4 at 7:53 AM

$VCYT Great piece that accurately captures VCYT's current position. So if you want to refresh your understanding of VCYT or learn about VCYT for the first time, this is essential reading. https://beyondspx.com/quote/VCYT/veracyte-genomic-diagnostics-powerhouse-forging-a-path-to-sustained-profitability-nasdaq-vcyt#analysis

0 · Reply

PhishTourFunds Aug. 23 at 1:59 PM

$VCYT

0 · Reply

PhishTourFunds Aug. 19 at 1:26 AM

$VCYT I dream about setups like that…

0 · Reply